Animal Model and Novel Approach Method (NAM) Development

This contract involves the development and validation of animal models and alternative methods, including in vitro and computational approaches, to investigate acute radiation syndrome and the delayed effects of radiation exposure. The aim is to conduct this research under the FDA Animal Efficacy Rule, which guides the evaluation of medical countermeasures in situations where human trials are not ethical or feasible. The contract is issued as a subcontract by the National Institutes of Health, specifically under the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services. The solicitation was posted in mid-May 2026, with responses due by early June 2026. The work falls under the NAICS code 541714, which covers research and development in biotechnology. While specific locations for the place of performance and points of contact are not provided, the contract’s focus is clearly on advancing scientific methods to better understand and mitigate radiation exposure effects, supporting regulatory requirements and potential therapeutic development.